When this barrier is damaged, fats can leak into your urine, making it look oily. A common cause of lipiduria is nephrotic syndrome, a kidney disorder that can be triggered by diabetes, lupus, or ...

Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis. Obinutuzumab, a monoclonal antibody that targets the CD20 receptor on B-cells, is ...

Introduction: Proliferative glomerulonephritis with monoclonal immunoglobulin ... Biochemical test showed proteinuria was 4446.7 mg/g by urine protein-creatinine ratio. Serum creatinine was 126 μmol/L ...

Kezar was testing the treatment, zetomipzomib, in patients with active lupus nephritis, a type of kidney disease caused by lupus - where the body's immune system attacks its own cells and organs.

Now, the company has hit the brakes on its phase 2b study of the drug in lupus nephritis following four patient fatalities. An independent data monitoring committee (IDMC) recommended suspending ...

We investigated its role in kidney inflammation and fibrosis in a murine model of lupus nephritis (LN), and the clinico-pathological ... Creatinine and Urea assay kits respectively. Spot urine was ...

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.

The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis – – Gazyva is designed to ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody ...

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis The REGENCY study met its primary endpoint, demonstrating ...